Who owns Prolyte ORS?
Prolyte ORS is owned by Cipla (India, NSE: CIPLA).[1]
This ownership is reported in official statements but has not yet been matched to a regulatory filing.
Evidence: Cipla Limited Integrated Annual Report 2025-26. Last checked .
Key facts
- Current owner
- Cipla Limited reported
- Owner HQ
- 🇮🇳 India, Mumbai
- Origin
- 🇮🇳 India
- Category
- Consumer health › Over-the-counter medicine › Digestive health
- Parent ticker
- NSE: CIPLA BSE: 500087
- Last verified
- · 2 sources
About Prolyte ORS
Prolyte ORS is an oral rehydration solution sold in India by Cipla Health, which describes it as a WHO-recommended formula for treating and preventing dehydration in children and adults. Cipla's 2025-26 annual report ranks it second in the Indian ORS market on AC Nielsen estimates as of January 2026.
Ownership timeline of Prolyte ORS
Where Prolyte ORS sits in Cipla
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Cipla ownership tree →
See the full Cipla brand portfolio (7) →
Other brands owned by Cipla
Cipla controls 7 brands on Brandtree, 5 of them in consumer health.
Also in consumer health
Other brands in digestive health, and who owns them
The 25 brands in digestive health on Brandtree belong to 18 owners. The largest is Bayer, with 2.
| Brand | Owner | Owner based in |
|---|---|---|
| Alka-Seltzer | Bayer | 🇩🇪 Germany |
| Daiichi Sankyo Stomach Medicine | Daiichi Sankyo Healthcare | 🇯🇵 Japan |
| Kaopectate | Genomma Lab | 🇲🇽 Mexico |
| Epocler | Hypera | 🇧🇷 Brazil |
| Entrostop | Kalbe Farma | 🇮🇩 Indonesia |
| Metamucil | Procter & Gamble | 🇺🇸 United States |
| Buscolysin | Sopharma | 🇧🇬 Bulgaria |
| Oracal | Birzeit Pharmaceutical | 🇵🇸 Palestine |
About the owner: Cipla
Cipla is a publicly listed company headquartered in Mumbai, India, founded in 1935. Brandtree records 7 brands under its control, and it is listed as NSE: CIPLA and BSE: 500087.
Cipla is a Mumbai drugmaker founded by Dr K A Hamied in August 1935. Its 2025-26 annual report calls it India's third-largest pharmaceutical company and second in the South African prescription market, with 48 manufacturing sites and over 31,000 permanent employees. Consolidated revenue was ₹28,163 crore in the year to 31 March 2026. Its Indian consumer health business is run by a wholly owned subsidiary, Cipla Health Limited.
🇮🇳 Prolyte ORS and other Indian brands
Brandtree records a controlling owner for 279 brands that began in India. 9 of them (3%) are now controlled by a company headquartered in another country; Prolyte ORS is not one of them.
- Ascoril — Glenmark 🇮🇳
- Gas-O-Fast — Mankind Pharma 🇮🇳
- Ibuclin — Dr. Reddy's 🇮🇳
- Mentho Plus — Emami 🇮🇳
- 8PM — Radico Khaitan 🇮🇳
- ACC — Ambuja Cements 🇮🇳
Frequently asked questions
Who is the parent company of Prolyte ORS?
The parent company of Prolyte ORS is Cipla, a publicly listed company headquartered in India.
Is Prolyte ORS Indian?
Yes. Prolyte ORS originated in India and its owner, Cipla, is also headquartered in India.
Is Prolyte ORS still owned by Cipla?
Yes. As of 21 October 2026, Prolyte ORS is still owned by Cipla. The ownership record was last checked against primary sources on that date.
Sources (2) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Cipla Limited Integrated Annual Report 2025-26 — Cipla Limited, Annual report; retrieved 21 October 2026.
- [2] Cipla Health — Our Brands — Cipla Health Limited, Official document; retrieved 21 October 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.